PE20142113A1 - Analogos de glucagon - Google Patents

Analogos de glucagon

Info

Publication number: PE20142113A1
Authority: PE; Peru
Prior art keywords: ser; leu; lys; asp; absent
Prior art date: 2011-12-23

Application number

PE2014000970A

Other languages

English (en)

Spanish (es)

Inventor

Dieter Wolfgang Hamprecht

Jakob Lind Tolborg

Ditte Riber

Original Assignee

Zealand Pharma As

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-23

Filing date

2012-12-19

Publication date

2014-12-03

2012-12-19 Application filed by Zealand Pharma As, Boehringer Ingelheim Int filed Critical Zealand Pharma As

2014-12-03 Publication of PE20142113A1 publication Critical patent/PE20142113A1/es

Links

MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical class C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Zoology (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

PE2014000970A 2011-12-23 2012-12-19 Analogos de glucagon PE20142113A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201161579888P	2011-12-23	2011-12-23

Publications (1)

Publication Number	Publication Date
PE20142113A1 true PE20142113A1 (es)	2014-12-03

Family

ID=47594620

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2014000970A PE20142113A1 (es)	2011-12-23	2012-12-19	Analogos de glucagon

Country Status (20)

Country	Link
US (2)	US20130316941A1 (2)
EP (1)	EP2793931A2 (2)
JP (1)	JP2015502380A (2)
KR (1)	KR20140114845A (2)
CN (1)	CN104144696A (2)
AP (2)	AP2014007797A0 (2)
AU (1)	AU2012357739A1 (2)
BR (1)	BR112014015681A2 (2)
CA (1)	CA2858949A1 (2)
EA (1)	EA201490982A1 (2)
HK (1)	HK1200369A1 (2)
IL (1)	IL232800A0 (2)
IN (1)	IN2014CN04401A (2)
MA (1)	MA35864B1 (2)
MX (1)	MX2014007120A (2)
PE (1)	PE20142113A1 (2)
PH (1)	PH12014501336A1 (2)
SG (1)	SG11201403377QA (2)
TN (1)	TN2014000224A1 (2)
WO (1)	WO2013092703A2 (2)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2010272944B2 (en)	2009-07-13	2015-11-19	Zealand Pharma A/S	Acylated glucagon analogues
UY33462A (es)	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon
US9169310B2 (en)	2010-06-24	2015-10-27	Zealand Pharma A/S	Glucagon analogues
IN2014MN02304A (2)	2012-05-03	2015-08-07	Zealand Pharma As
EP2664374A1 (en) *	2012-05-15	2013-11-20	F. Hoffmann-La Roche AG	Lysin-glutamic acid dipeptide derivatives
IN2015DN00544A (2)	2012-07-23	2015-06-26	Zealand Pharma As
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
GB201315335D0 (en)	2013-08-29	2013-10-09	Of Singapore	Amino diacids containing peptide modifiers
PL3057984T3 (pl)	2013-10-17	2018-12-31	Zealand Pharma A/S	Acylowane analogi glukagonu
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
WO2015067715A2 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
CN105829339B (zh)	2013-11-06	2021-03-12	西兰制药公司	胰高血糖素-glp-1-gip三重激动剂化合物
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
TW201625668A (zh) *	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
KR102620911B1 (ko)	2014-10-29	2024-01-05	질랜드 파마 에이/에스	Gip 효능제 화합물 및 방법
TWI582109B (zh) *	2015-01-09	2017-05-11	美國禮來大藥廠	Ｇｉｐ及ｇｌｐ－１共促效劑化合物
BR112017014994B1 (pt)	2015-02-17	2023-12-19	Eli Lilly And Company	Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
BR112017019378A2 (pt)	2015-03-18	2019-02-19	Zealand Pharma A/S	análogos de amilina
WO2016168388A2 (en)	2015-04-14	2016-10-20	Palatin Technologies, Inc.	Therapies for obesity, diabetes and related indications
DK3283507T3 (da)	2015-04-16	2020-01-02	Zealand Pharma As	Acyleret glucagonanalog
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en)	2015-06-12	2016-12-15	Sanofi	Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en)	2015-06-12	2016-12-15	Sanofi	Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
TWI622596B (zh) *	2015-10-26	2018-05-01	美國禮來大藥廠	升糖素受體促效劑
US11179444B2 (en)	2016-06-09	2021-11-23	Amidebio, Llc	Glucagon analogs and methods of use thereof
SG11201811804QA (en)	2016-08-05	2019-01-30	Boehringer Ingelheim Int	Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
US10071140B2 (en)	2016-09-09	2018-09-11	Zealand Pharma A/S	Amylin analogues
EP3551651B1 (en) *	2016-12-09	2024-03-06	Zealand Pharma A/S	Acylated glp-1/glp-2 dual agonists
SG11202001283PA (en) *	2017-08-16	2020-03-30	Dong A St Co Ltd	Acylated oxyntomodulin peptide analog
MX2020007994A (es)	2018-02-02	2020-09-09	Boehringer Ingelheim Int	Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
AU2019215707A1 (en)	2018-02-02	2020-07-09	Boehringer Ingelheim International Gmbh	Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors
WO2019149659A1 (en)	2018-02-02	2019-08-08	Boehringer Ingelheim International Gmbh	Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
EP3746449B1 (en)	2018-02-02	2022-03-30	Boehringer Ingelheim International GmbH	Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CN111349155B (zh) *	2018-12-24	2022-04-05	浙江和泽医药科技股份有限公司	一种胰高血糖素类似物及其制备方法和用途
TWI771669B (zh)	2019-04-26	2022-07-21	美商美國禮來大藥廠	製備穩定胜肽調配物之方法
GB201908424D0 (en)	2019-06-12	2019-07-24	Imp College Innovations Ltd	Novel compounds
CR20220206A (es)	2019-11-11	2022-06-16	Boehringer Ingelheim Int	Agonistas del receptor npy2
WO2021233882A1 (en)	2020-05-22	2021-11-25	Boehringer Ingelheim International Gmbh	Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
CN115916789B (zh)	2020-05-22	2025-06-27	勃林格殷格翰国际有限公司	制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法
CN113292646B (zh) *	2020-05-29	2022-05-13	东莞云璟生物技术有限公司	Glp-1/胰高血糖素双重激动剂融合蛋白
JP7661478B2 (ja)	2020-08-07	2025-04-14	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	可溶性ｎｐｙ２受容体アゴニスト

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU723268B2 (en)	1996-09-09	2000-08-24	Zealand Pharma A/S	Improved solid-phase peptide synthesis and agent for use in such synthesis
NZ506839A (en)	1998-03-09	2003-05-30	Zealand Pharma As	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
ATE553124T1 (de)	2005-06-13	2012-04-15	Imp Innovations Ltd	Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
CA2638800A1 (en)	2006-02-22	2007-09-07	Merck & Co., Inc.	Oxyntomodulin derivatives
MX2009000709A (es)	2006-07-18	2009-02-04	Sanofi Aventis	Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
CA2677932A1 (en)	2007-02-15	2008-08-21	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
EP2158214B1 (en)	2007-06-15	2011-08-17	Zealand Pharma A/S	Glucagon analogues
AR072160A1 (es)	2008-06-17	2010-08-11	Univ Indiana Res & Tech Corp	Co-agonistas del receptor de glucagon/glp-1
US8450270B2 (en)	2008-06-17	2013-05-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
EP2370462B1 (en) *	2008-12-15	2014-07-16	Zealand Pharma A/S	Glucagon analogues
AU2010272944B2 (en) *	2009-07-13	2015-11-19	Zealand Pharma A/S	Acylated glucagon analogues
US20130157953A1 (en) *	2010-01-20	2013-06-20	Zealand Pharma A/S	Treatment of cardiac conditions
UY33462A (es) *	2010-06-23	2012-01-31	Zealand Pharma As	Analogos de glucagon

2012
- 2012-12-19 IN IN4401CHN2014 patent/IN2014CN04401A/en unknown
- 2012-12-19 WO PCT/EP2012/076137 patent/WO2013092703A2/en not_active Ceased
- 2012-12-19 MX MX2014007120A patent/MX2014007120A/es unknown
- 2012-12-19 PE PE2014000970A patent/PE20142113A1/es not_active Application Discontinuation
- 2012-12-19 US US13/720,041 patent/US20130316941A1/en not_active Abandoned
- 2012-12-19 CN CN201280063090.8A patent/CN104144696A/zh active Pending
- 2012-12-19 AU AU2012357739A patent/AU2012357739A1/en not_active Abandoned
- 2012-12-19 KR KR1020147020623A patent/KR20140114845A/ko not_active Withdrawn
- 2012-12-19 SG SG11201403377QA patent/SG11201403377QA/en unknown
- 2012-12-19 EP EP12816470.4A patent/EP2793931A2/en not_active Withdrawn
- 2012-12-19 JP JP2014547973A patent/JP2015502380A/ja active Pending
- 2012-12-19 EA EA201490982A patent/EA201490982A1/ru unknown
- 2012-12-19 BR BR112014015681A patent/BR112014015681A2/pt not_active IP Right Cessation
- 2012-12-19 CA CA2858949A patent/CA2858949A1/en not_active Abandoned
- 2012-12-19 AP AP2014007797A patent/AP2014007797A0/xx unknown
- 2012-12-19 HK HK15101109.9A patent/HK1200369A1/xx unknown
2014
- 2014-05-21 TN TNP2014000224A patent/TN2014000224A1/en unknown
- 2014-05-26 IL IL232800A patent/IL232800A0/en unknown
- 2014-06-11 PH PH12014501336A patent/PH12014501336A1/en unknown
- 2014-07-09 AP AP2014007774A patent/AP2014007774A0/xx unknown
- 2014-07-11 MA MA37205A patent/MA35864B1/fr unknown
2016
- 2016-08-17 US US15/239,154 patent/US20160347813A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IN2014CN04401A (2)	2015-09-04
AU2012357739A1 (en)	2014-07-03
MA35864B1 (fr)	2014-12-01
HK1200369A1 (en)	2015-10-09
JP2015502380A (ja)	2015-01-22
BR112014015681A2 (pt)	2019-09-24
CN104144696A (zh)	2014-11-12
SG11201403377QA (en)	2014-07-30
AP2014007774A0 (en)	2014-07-31
CA2858949A1 (en)	2013-06-27
KR20140114845A (ko)	2014-09-29
MX2014007120A (es)	2015-03-05
TN2014000224A1 (en)	2015-09-30
US20160347813A1 (en)	2016-12-01
PH12014501336A1 (en)	2014-09-15
WO2013092703A2 (en)	2013-06-27
IL232800A0 (en)	2014-07-31
EP2793931A2 (en)	2014-10-29
EA201490982A1 (ru)	2015-01-30
AP2014007797A0 (en)	2014-07-31
US20130316941A1 (en)	2013-11-28
WO2013092703A3 (en)	2013-11-14

Legal Events

Date	Code	Title	Description
2015-06-05	FA	Abandonment or withdrawal

Publication	Publication Date	Title
PE20142113A1 (es)	2014-12-03	Analogos de glucagon
AR105816A2 (es)	2017-11-15	Derivados de exendina-4 funcionalizada
AR098739A1 (es)	2016-06-08	Análogos del péptido exendina-4 como agonistas duales del receptor de glp-1 / glp (péptido similar al glucagón tipo 1 / glucagón)
AR098737A1 (es)	2016-06-08	Agonistas duales del receptor de glp-1 / gip
AR099976A1 (es)	2016-08-31	Agonistas peptídicos duales de los receptores de glp-1 / glucagón derivados de la exendina-4
PE20130326A1 (es)	2013-03-17	Analogos de glucagon
AR098740A1 (es)	2016-06-08	Análogos del péptido exendina-4
PE20231639A1 (es)	2023-10-16	Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1)
HRP20201353T1 (hr)	2020-11-27	Agonisti glukagonskog receptora
AR091866A1 (es)	2015-03-04	Analogos del glucagon
AR099975A1 (es)	2016-08-31	Derivados de exendina-4 como agonistas peptídicos duales del receptor de glp-1 / glucagón
TN2012000215A1 (en)	2013-12-12	Pharmaceutical compositions comprising a g l p -1 agonist and methionine
AR096440A1 (es)	2015-12-30	Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip)
AR115939A2 (es)	2021-03-17	Composición que contiene palmitoil-etanolamida ultra-micronizada
PE20211300A1 (es)	2021-07-20	Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
PE20121130A1 (es)	2012-08-30	Analogos de glucagon acilados
MX366405B (es)	2019-07-08	Uso de peptidos glp-1 de accion prolongada.
NI201100213A (es)	2012-08-03	Péptidos específicos para receptores de melanocortina
AR067555A1 (es)	2009-10-14	Derivado de peptido insulinotropico en el cual se modifica su aminoacido n- terminal
MX369259B (es)	2019-11-04	Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
PE20140724A1 (es)	2014-07-10	Coagonistas del receptor de glucagon/glp-1
MX377410B (es)	2025-03-10	Antagonistas de receptores de integrina y sus metodos de uso.
CL2012002031A1 (es)	2012-12-14	Composición farmacéutica que contiene al menos un compuesto fgf-21 (factor de crecimiento de fibroblastos 21) y al menos un agonista del glp-1r (receptor del péptido 1 similar al glucagón); y su uso para preparara un medicamento para el tratamiento de al menos un síndrome metabólico y/o aterosclerosis en un paciente.
CL2011001498A1 (es)	2012-03-09	Profarmaco que comprende la estructura a-b-q donde q es un peptido de la superfamilia de glucagon, a es un aminoacido o un hidroxiacido y b es un aminoacido n-alquilado ligado a q; composicion farmaceutica que comprende el profarmaco; metodo para suprimir el apetito o inducir la perdida de peso.
GT201200263A (es)	2013-12-05	"nuevos peptidos y metodos para su preparacion y uso"